Immunovia Reports Interim Report January – March 2021
LUND (SWEDEN) – Immunovia has today published its interim report for the period January 1 – March 31, 2021. It is available on Immunovia’s website .
Patrik Dahlen, CEO Immunovia:
“Thanks to the great efforts of our employees, we achieved significant success during Q1 for our blood test IMMray™ PanCan-d. We reached the final milestone in the development phase and the next step was to apply for CLIA certification for IMMray™ PanCan-d to receive market approval in the US. In addition, we have worked to improve the performance of the